Cargando…
Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?
γ-Secretase inhibitors are new anti-cancer agents targeting Notch signaling. Their specificity for Notch is as yet unclear. Han and colleagues investigated the effects of Z-LeuLeuNleu-CHO on growth of breast cancer cells. The results demonstrated a reduction in cell viability primarily via proteasom...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790851/ https://www.ncbi.nlm.nih.gov/pubmed/19849815 http://dx.doi.org/10.1186/bcr2407 |
_version_ | 1782175138948579328 |
---|---|
author | Clementz, Anthony G Osipo, Clodia |
author_facet | Clementz, Anthony G Osipo, Clodia |
author_sort | Clementz, Anthony G |
collection | PubMed |
description | γ-Secretase inhibitors are new anti-cancer agents targeting Notch signaling. Their specificity for Notch is as yet unclear. Han and colleagues investigated the effects of Z-LeuLeuNleu-CHO on growth of breast cancer cells. The results demonstrated a reduction in cell viability primarily via proteasome inhibition independent of Notch activity. Currently, γ-secretase inhibitors in clinical trials are structurally distinct from Z-LeuLeuNleu-CHO. Their effects on the proteasome are yet to be determined. However, findings from Han and colleagues pose two critical questions: Is the level of proteasomal activity in breast tumors the driving force for growth? What does the Notch pathway contribute to this growth? |
format | Text |
id | pubmed-2790851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-27908512009-12-10 Notch versus the proteasome: what is the target of γ-secretase inhibitor-I? Clementz, Anthony G Osipo, Clodia Breast Cancer Res Editorial γ-Secretase inhibitors are new anti-cancer agents targeting Notch signaling. Their specificity for Notch is as yet unclear. Han and colleagues investigated the effects of Z-LeuLeuNleu-CHO on growth of breast cancer cells. The results demonstrated a reduction in cell viability primarily via proteasome inhibition independent of Notch activity. Currently, γ-secretase inhibitors in clinical trials are structurally distinct from Z-LeuLeuNleu-CHO. Their effects on the proteasome are yet to be determined. However, findings from Han and colleagues pose two critical questions: Is the level of proteasomal activity in breast tumors the driving force for growth? What does the Notch pathway contribute to this growth? BioMed Central 2009 2009-10-15 /pmc/articles/PMC2790851/ /pubmed/19849815 http://dx.doi.org/10.1186/bcr2407 Text en Copyright ©2009 BioMed Central Ltd |
spellingShingle | Editorial Clementz, Anthony G Osipo, Clodia Notch versus the proteasome: what is the target of γ-secretase inhibitor-I? |
title | Notch versus the proteasome: what is the target of γ-secretase inhibitor-I? |
title_full | Notch versus the proteasome: what is the target of γ-secretase inhibitor-I? |
title_fullStr | Notch versus the proteasome: what is the target of γ-secretase inhibitor-I? |
title_full_unstemmed | Notch versus the proteasome: what is the target of γ-secretase inhibitor-I? |
title_short | Notch versus the proteasome: what is the target of γ-secretase inhibitor-I? |
title_sort | notch versus the proteasome: what is the target of γ-secretase inhibitor-i? |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790851/ https://www.ncbi.nlm.nih.gov/pubmed/19849815 http://dx.doi.org/10.1186/bcr2407 |
work_keys_str_mv | AT clementzanthonyg notchversustheproteasomewhatisthetargetofgsecretaseinhibitori AT osipoclodia notchversustheproteasomewhatisthetargetofgsecretaseinhibitori |